168 related articles for article (PubMed ID: 19879210)
21. GLP-1 receptor agonists: targeting both hyperglycaemia and disease processes in diabetes.
Holst JJ; Seino Y
Diabetes Res Clin Pract; 2009 Jul; 85(1):1-3. PubMed ID: 19299027
[No Abstract] [Full Text] [Related]
22. Physiological and pharmacological mechanisms through which the DPP-4 inhibitor sitagliptin regulates glycemia in mice.
Waget A; Cabou C; Masseboeuf M; Cattan P; Armanet M; Karaca M; Castel J; Garret C; Payros G; Maida A; Sulpice T; Holst JJ; Drucker DJ; Magnan C; Burcelin R
Endocrinology; 2011 Aug; 152(8):3018-29. PubMed ID: 21673098
[TBL] [Abstract][Full Text] [Related]
23. Acute dipeptidyl peptidase-4 inhibition rapidly enhances insulin-mediated suppression of endogenous glucose production in mice.
Duez H; Smith AC; Xiao C; Giacca A; Szeto L; Drucker DJ; Lewis GF
Endocrinology; 2009 Jan; 150(1):56-62. PubMed ID: 18801896
[TBL] [Abstract][Full Text] [Related]
24. Novel GPR40 agonist AS2575959 exhibits glucose metabolism improvement and synergistic effect with sitagliptin on insulin and incretin secretion.
Tanaka H; Yoshida S; Minoura H; Negoro K; Shimaya A; Shimokawa T; Shibasaki M
Life Sci; 2014 Jan; 94(2):115-21. PubMed ID: 24269216
[TBL] [Abstract][Full Text] [Related]
25. GLP-1-Based Therapies Have No Microvascular Effects in Type 2 Diabetes Mellitus: An Acute and 12-Week Randomized, Double-Blind, Placebo-Controlled Trial.
Smits MM; Tonneijck L; Muskiet MH; Hoekstra T; Kramer MH; Diamant M; Serné EH; van Raalte DH
Arterioscler Thromb Vasc Biol; 2016 Oct; 36(10):2125-32. PubMed ID: 27562916
[TBL] [Abstract][Full Text] [Related]
26. Evaluating insulin secretagogues in a humanized mouse model with functional human islets.
Luo J; Nguyen K; Chen M; Tran T; Hao J; Tian B; Rulifson IC; Zhang Y; Tian L; Zhang Y; Lopez E; Lin DC; Wang Y; Ma Z; Houze J; Guo Z
Metabolism; 2013 Jan; 62(1):90-9. PubMed ID: 22982177
[TBL] [Abstract][Full Text] [Related]
27. Medicinal Chemistry of Incretin Mimetics and DPP-4 Inhibitors.
Zettl H; Schubert-Zsilavecz M; Steinhilber D
ChemMedChem; 2010 Feb; 5(2):179-85. PubMed ID: 20029928
[No Abstract] [Full Text] [Related]
28. [Incretin-based therapy for treating patients with type 2 diabetes].
Jermendy G
Orv Hetil; 2011 Nov; 152(48):1931-40. PubMed ID: 22071295
[TBL] [Abstract][Full Text] [Related]
29. Incretin-based therapies in the management of type 2 diabetes: rationale and reality in a managed care setting.
Garber AJ
Am J Manag Care; 2010 Aug; 16(7 Suppl):S187-94. PubMed ID: 20809667
[TBL] [Abstract][Full Text] [Related]
30. Distinguishing among incretin-based therapies. Patient education and self-management.
Campbell RK; Cobble ME; Reid TS; Shomali ME
J Fam Pract; 2010 Sep; 59(9 Suppl 1):S28-30. PubMed ID: 20824237
[TBL] [Abstract][Full Text] [Related]
31. Advances in therapy for type 2 diabetes: GLP-1 receptor agonists and DPP-4 inhibitors.
Davidson JA
Cleve Clin J Med; 2009 Dec; 76 Suppl 5():S28-38. PubMed ID: 19952301
[TBL] [Abstract][Full Text] [Related]
32. Sitagliptin exerts an antinflammatory action.
Makdissi A; Ghanim H; Vora M; Green K; Abuaysheh S; Chaudhuri A; Dhindsa S; Dandona P
J Clin Endocrinol Metab; 2012 Sep; 97(9):3333-41. PubMed ID: 22745245
[TBL] [Abstract][Full Text] [Related]
33. Dipeptidyl peptidase IV inhibition activates CREB and improves islet vascularization through VEGF-A/VEGFR-2 signaling pathway.
Samikannu B; Chen C; Lingwal N; Padmasekar M; Engel FB; Linn T
PLoS One; 2013; 8(12):e82639. PubMed ID: 24349326
[TBL] [Abstract][Full Text] [Related]
34. Distinguishing among incretin-based therapies. Glucose-lowering effects of incretin-based therapies.
Campbell RK; Cobble ME; Reid TS; Shomali ME
J Fam Pract; 2010 Sep; 59(9 Suppl 1):S10-9. PubMed ID: 20824235
[TBL] [Abstract][Full Text] [Related]
35. Incretin-based treatment of type 2 diabetes: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors.
Deacon CF
Diabetes Obes Metab; 2007 Sep; 9 Suppl 1():23-31. PubMed ID: 17877544
[TBL] [Abstract][Full Text] [Related]
36. Role of the incretin pathway in the pathogenesis of type 2 diabetes mellitus.
Freeman JS
Cleve Clin J Med; 2009 Dec; 76 Suppl 5():S12-9. PubMed ID: 19952298
[TBL] [Abstract][Full Text] [Related]
37. Sitagliptin: profile of a novel DPP-4 inhibitor for the treatment of type 2 diabetes (update).
Gallwitz B
Drugs Today (Barc); 2007 Nov; 43(11):801-14. PubMed ID: 18174966
[TBL] [Abstract][Full Text] [Related]
38. Impact of incretin therapy on islet dysfunction: an underlying defect in the pathophysiology of type 2 diabetes.
McGill JB
Postgrad Med; 2009 Jan; 121(1):46-58. PubMed ID: 19179813
[TBL] [Abstract][Full Text] [Related]
39. Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4).
Thornberry NA; Gallwitz B
Best Pract Res Clin Endocrinol Metab; 2009 Aug; 23(4):479-86. PubMed ID: 19748065
[TBL] [Abstract][Full Text] [Related]
40. Patient-reported outcomes in trials of incretin-based therapies in patients with type 2 diabetes mellitus.
Davies M; Speight J
Diabetes Obes Metab; 2012 Oct; 14(10):882-92. PubMed ID: 22420869
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
